Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ONC with free AI briefings, catalyst countdowns, and dilution alerts.

ONC · BeOne Medicines Ltd.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$5.8B Cash on Hand
CF+ Cash Runway
Follow ONC by email Get an email when ONC reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ONC, unsubscribe in one click. Privacy

📣 What ONC Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Sonrotoclax
FDA approved May 2026 · Beqalzi
CLL Phase 3 · NCT06073821 Active not recruiting
CDK4 Inhibitor BGB-43395 HR+/HER2- Breast Cancer Phase 3 · NCT07492641 Recruiting
Anti-GPC3/Anti-4-1BB Bispecific Antibody… Hepatocellular Carcinoma Phase 3 · NCT07836530 Recruiting
Tacabrutideg Chronic Lymphocytic Leukemia Phase 3 · NCT06973187 Recruiting
Cytotoxic Chemotherapeutic Agent Non-small Cell Lung Cancer Metastatic Phase 3 · NCT07715396 Not yet recruiting
Fluorouracil Gastric Neoplasms Phase 3 · NCT05152147 Active not recruiting
Nab-paclitaxel Non-Small Cell Lung Cancer (NSCLC) Phase 2 · NCT07885709 Not yet recruiting
PD1 Inhibitor Non-Small Cell Lung Cancer (NSCLC) Phase 2 · NCT07885709 Not yet recruiting
Programmed Cell Death Protein 1 Borderline Resectable Carcinoma Phase 2 · NCT07339488 Recruiting
Catequentinib Non-Small Cell Lung Cancer (NSCLC) Phase 2 · NCT07885709 Not yet recruiting
Chimeric Antigen Receptor T-cells Mantle Cell Lymphoma Phase 2 · NCT07341191 Recruiting
BG-T0050 Diffuse Large B-Cell Lymphoma Phase 1 · NCT07881211 Not yet recruiting
PRMT5 Inhibitor BGB-58067 Healthy Volunteers Phase 1 · NCT07712640 Recruiting
Rosuvastatin Healthy Adult Participants Phase 1 · NCT07820891 Recruiting
Anti-CEACAM5 Antibody-drug Conjugate BG-C477 Advanced Solid Tumors Phase 1 · NCT06596473 Recruiting
BG-92505 Advanced Solid Tumor Phase 1 · NCT07896460 Not yet recruiting

Also used in these trials (approved or third-party drugs, not ONC's own candidates): Lenvatinib, Letrozole, Leucovorin, Cisplatin, Obinutuzumab, Oxaliplatin, Capecitabine, Palbociclib, Lenalidomide, Tislelizumab, Pembrolizumab, Pirtobrutinib.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ONC holds $5.8B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ONC files for a raise →

👥 Who Owns ONC

Insiders 0.4% Institutions (425 holders) 32.5% Public and other holders 67.1%
HolderTypeShares% of sharesAs of
Julian C. Baker Institution (13G, 5%+) 115,912,814 7.81% 2026-09-14
Xiaodong Wang
Director · +193,492 options
Insider 4,586,980 0.31% 2026-11-09
Lai Wang
President, Global Head of R&D · +229,775 options
Insider 601,965 0.04% 2026-06-23
BAKER BROS. ADVISORS LP
Director
Insider 323,097 0.02% 2026-09-14
John Oyler
Chief Executive Officer, Director · +344,679 options
Insider 102,188 0.01% 2026-08-10
Anthony C Hooper
Director
Insider 83,720 0.01% 2026-06-11
Margaret Dugan
Director
Insider 73,164 0.00% 2026-06-11
Alessandro Riva
Director
Insider 73,164 0.00% 2026-06-11
Olivier Brandicourt
Director
Insider 46,306 0.00% 2026-06-11
Elizabeth Fisher Mooney
Director
Insider 18,980 0.00% 2026-06-11
Xiaobin Wu
President and COO · +229,775 options
Insider 4,000 0.00% 2026-08-25
Charles Lazelle Sawyers
Director
Insider 1,946 0.00% 2026-06-11

Share count 1,484,939,031 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ONC picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ONC and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.